封面
市场调查报告书
商品编码
1719172

地中海贫血治疗市场-全球产业规模、份额、趋势、机会和预测(按治疗、类型、最终用户、地区和竞争细分,2020-2030 年)

Thalassemia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Type, By End User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球地中海贫血治疗市场价值为 9.0105 亿美元,预计到 2030 年将达到 14.192 亿美元,预测期内复合年增长率为 7.84%。市场正在经历一场转型,推动力包括诊断率的提高、医疗保健服务的改善以及公共和私人部门为治疗罕见遗传疾病所做的努力的不断扩大。患者和医疗保健提供者的意识增强有助于早期筛检和及时干预。虽然输血仍然是核心治疗方式,但螯合疗法的进步已经提高了长期安全性和治疗效果。製药公司正在积极开发像luspatercept和mitapivat这样的疗法,以减少输血依赖并增加血红素的生成。同时,新兴市场正在加强规范输血服务的基础设施,促进更广泛地采用综合护理模式,并推动全球市场成长。

市场概览
预测期 2026-2030
2024年市场规模 9.0105亿美元
2030年市场规模 14.192亿美元
2025-2030 年复合年增长率 7.84%
成长最快的领域 α地中海贫血
最大的市场 北美洲

关键市场驱动因素

全球地中海贫血盛行率上升

主要市场挑战

获得先进疗法的机会有限

主要市场趋势

基因编辑疗法的出现

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:全球地中海贫血治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗方法(铁螯合药物、输血、红血球成熟剂、干细胞疗法等)
    • 依类型(α地中海贫血、β地中海贫血)
    • 按最终使用者(医院、研究机构、其他)
    • 按公司分类(2024)
    • 按地区
  • 市场地图

第六章:北美地中海贫血治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章:欧洲地中海贫血治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章:亚太地区地中海贫血治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章:南美洲地中海贫血治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章:中东与非洲地中海贫血治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 合併与收购(如有)
  • 产品发布(如有)
  • 最新动态

第 13 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章:竞争格局

  • Bluebird Bio, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • ApoPharma Inc.
  • Pfizer, Inc.
  • Celgene Corporation
  • Takeda Pharmaceuticals Company Limited
  • Incyte Corporation
  • Bellicum Pharmaceuticals
  • GSK plc

第 15 章:策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 15590

The Global Thalassemia Treatment Market was valued at USD 901.05 Million in 2024 and is projected to reach USD 1,419.20 Million by 2030, growing at a CAGR of 7.84% during the forecast period. The market is undergoing a transformation driven by increasing diagnosis rates, improved healthcare access, and expanding public and private efforts to manage rare genetic disorders. Enhanced awareness among patients and healthcare providers is encouraging early screening and timely intervention. While blood transfusions remain a core treatment modality, advancements in chelation therapies have improved long-term safety and outcomes. Pharmaceutical companies are actively developing therapies like luspatercept and mitapivat to reduce transfusion dependency and increase hemoglobin production. Simultaneously, emerging markets are enhancing infrastructure for regulated transfusion services, contributing to a broader adoption of comprehensive care models and fueling global market growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 901.05 Million
Market Size 2030USD 1,419.20 Million
CAGR 2025-20307.84%
Fastest Growing SegmentAlpha Thalassemia
Largest MarketNorth America

Key Market Drivers

Rising Global Prevalence of Thalassemia

The growing global prevalence of thalassemia is a major driver of market expansion. Thalassemia, a genetic blood disorder, is most prevalent in regions such as Southeast Asia, the Mediterranean, the Middle East, and North Africa. According to the World Health Organization (WHO), approximately 5% of the global population carries the thalassemia gene, contributing to increasing case numbers, especially in areas lacking genetic counseling or prenatal screening. As diagnosis rates improve, demand for lifelong care-including regular transfusions and iron chelation therapy-is rising. In parallel, innovative treatments such as stem cell transplantation and gene therapy are gaining attention as potential curative options. Governments and health organizations are investing in early detection programs, public health campaigns, and treatment facilities, all of which are fueling sustained market growth by ensuring better access to thalassemia care.

Key Market Challenges

Limited Access to Advanced Therapies

A significant challenge facing the thalassemia treatment market is the limited access to advanced therapies, particularly in low- and middle-income regions. While gene therapies and stem cell transplants offer promising long-term outcomes or potential cures, their availability is often restricted due to high costs, complex infrastructure requirements, and the need for specialized medical expertise. These therapies are financially inaccessible for many patients, with prices often reaching hundreds of thousands of dollars. Moreover, resource-poor regions lack the necessary facilities and personnel to support advanced treatments, leaving patients dependent on traditional methods like blood transfusions and iron chelation, which are less effective over the long term. This disparity in care contributes to uneven patient outcomes and underscores the need for global strategies to improve accessibility, affordability, and infrastructure for advanced thalassemia therapies.

Key Market Trends

Emergence of Gene Editing Therapies

Gene editing therapies, particularly CRISPR-Cas9, are emerging as transformative innovations in the treatment of thalassemia. These techniques allow precise modification of defective genes responsible for the disease, offering the potential for a one-time curative approach. Traditional therapies manage symptoms without addressing the genetic root cause, whereas gene editing targets and corrects the underlying mutation. In 2023, clinical trials showed positive outcomes using CRISPR-Cas9 to treat beta-thalassemia, significantly reducing or eliminating transfusion needs. Companies like CRISPR Therapeutics and Vertex Pharmaceuticals are advancing therapies such as CTX001, which modifies patient stem cells to promote functional hemoglobin production. These advancements mark a shift toward personalized, curative treatments that could redefine long-term disease management. As regulatory pathways for orphan drugs and genetic therapies evolve, these approaches are expected to play a larger role in the future of thalassemia care.

Key Market Players

  • Bluebird Bio, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • ApoPharma Inc.
  • Pfizer, Inc.
  • Celgene Corporation
  • Takeda Pharmaceuticals Company Limited
  • Incyte Corporation
  • Bellicum Pharmaceuticals
  • GSK plc

Report Scope

In this report, the Global Thalassemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Thalassemia Treatment Market, By Treatment:

  • Iron Chelating Drugs
  • Blood Transfusions
  • Erythyroid Maturation Agents
  • Stem Cell Therapy
  • Others

Thalassemia Treatment Market, By Type:

  • Alpha Thalassemia
  • Beta Thalassemia

Thalassemia Treatment Market, By End User:

  • Hospitals
  • Research Institutes
  • Others

Thalassemia Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Thalassemia Treatment Market.

Available Customizations

Global Thalassemia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Thalassemia Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Iron Chelating Drugs, Blood Transfusions, Erythyroid Maturation Agents, Stem Cell Therapy, Others)
    • 5.2.2. By Type (Alpha Thalassemia, Beta Thalassemia)
    • 5.2.3. By End User (Hospitals, Research Institutes, Others)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Thalassemia Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Thalassemia Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Thalassemia Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Thalassemia Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End User

7. Europe Thalassemia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Thalassemia Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Thalassemia Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Thalassemia Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Thalassemia Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Thalassemia Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End User

8. Asia-Pacific Thalassemia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Thalassemia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Thalassemia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea Thalassemia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan Thalassemia Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Thalassemia Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. South America Thalassemia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Thalassemia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Thalassemia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Thalassemia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User

10. Middle East and Africa Thalassemia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Thalassemia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Thalassemia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Thalassemia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Bluebird Bio, Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Merck & Co., Inc.
  • 14.3. Novartis AG
  • 14.4. ApoPharma Inc.
  • 14.5. Pfizer, Inc.
  • 14.6. Celgene Corporation
  • 14.7. Takeda Pharmaceuticals Company Limited
  • 14.8. Incyte Corporation
  • 14.9. Bellicum Pharmaceuticals
  • 14.10. GSK plc

15. Strategic Recommendations

16. About Us & Disclaimer